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Abstract
Introduction: Patients with congenital heart disease who
underwent pulmonary valvotomy or surgery to open the
pulmonary valve ring are prone to develop residual
pulmonary insufficiency or stenosis that may lead to right
heart failure with clinical deterioration. These children
require multiple interventions throughout their lives, which
impose a high rate of morbidity and mortality.
Objective: To develop a less invasive technique for
implantation of a valved prosthesis through the right
ventricle.
Methods: The valved prosthesis consists of an auto-
expanding metal stent built with nitinol, surrounded with
polyester, where the three leaflets of bovine pericardium
were mounted. Twelve pigs were used to perform the
implants. Echocardiographic control was performed
immediately after implantation and one, four, eight and 12
weeks.
Results: One animal showed reflux of moderate to severe
and three mild reflux. Transvalvular gradients measured
before implantation ranged from 3 to 6 mmHg and that soon
after the implant was increased, ranging from 7 to 45 mmHg.
There was a decrease in these gradients during follow up
and in only four of the twelve animals the gradients were
above 20 mmHg. Thrombus formation occurred in the
prosthesis of six animals, and this was the most frequent
complication.
Conclusion: These findings highlight the need for studies
with the use of anticoagulants and antiplatelet, an attempt
to reduce this event. The study aims to contribute for the
start of the use of prosthetic heart valves that could be
implanted through minimally invasive techniques without
the use of cardiopulmonary bypass.
Descriptors: Pulmonary Valve Insufficiency. Pulmonary
Surgical Procedures. Pulmonary Valve Stenosis.
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INTRODUCTION
The extraordinary advances in cardiac surgery in non-
invasive diagnostic and intensive care over the past 50
years have a worldwide growth in the number of patients
with congenital heart disease who reach adolescence and
adulthood. It is expected that approximately 85% of children
born with congenital heart defects will survive to adulthood,
and with the continued improvement in surgical techniques,
this number may increase further in the next two decades
[1]. It is estimated that currently there are around 856,000
adults with congenital heart disease in the United States of
America [2].
The dysfunction of right ventricular outflow tract
(RVOT) with pulmonary stenosis or insufficiency is a
condition often found in the follow-up of patients, children
and adults undergoing repair of complex congenital heart
disease, especially in diseases that present with some
degree of obstruction to pulmonary flow, either subvalvular,
valvular or supravalvular. As a rule, these patients require
enlargement of he RVOT for correction, either by expanding
this or the interposition of valved conduits between the
right ventricle and pulmonary artery. In follow-up of patients
with pulmonary stenosis, varying degrees of pulmonary
insufficiency are found in more than 70% of patients,
regardless of the technique used in its correction [3-6]. The
same is true for patients undergoing repair of tetralogy of
Fallot, which are almost invariably present with pulmonary
insufficiency, which may be important in moderate to 50%
of cases [7].
The residual pulmonary insufficiency in the early
postoperative period of the diseases that require the
RVOT enlargement or pulmonary valvuloplasty was long
assumed to be a normal consequence, with benign
evolution and acceptable in the early stages of congenital
heart surgery. However, follow-up studies have shown
long-term hemodynamic deleterious effects on right and
left ventricular function [8,9], which results in decreased
ability to exercise, which often precedes the onset of
symptoms of heart failure, dyspnea, arrhythmias and
sudden death [10,11].
The surgical indications for pulmonary valve
replacement in these patients is a challenge. The use of
cardiopulmonary bypass (CPB) may exacerbate the
dysfunction of the right ventricle, with worsening symptoms
and decreased survival in the postoperative period. Valve
replacement options consist of performance of prosthetic
implants, both metallic or biological prosthesis in the
interposition of a homograft, xenograft or simple
enlargement of the outflow in young children. Regardless
of the technique used for the treatment, these children
require multiple interventions throughout their lives, which
imposes a high rate of morbidity and mortality.
Percutaneous treatment of RVOT dysfunction has
emerged as an alternative to conventional surgical treatment.
Initial studies were developed by Bonhoeffer et al. [12] in
2000, with the use of bovine jugular vein mounted on a
balloon expandable stent made of stainless steel, for
percutaneous implantation. From this initial study, the first
series of cases in humans have demonstrated the
applicability of this method for the treatment of patients
with severe pulmonary regurgitation and or residual
pulmonary stenosis, with low rates of morbidity and
mortality [13-16].
Resumo
Introdução: Nos pacientes portadores de cardiopatias
congênitas que foram submetidos à valvotomia pulmonar
ou cirurgias de ampliação com o uso do anel da válvula
pulmonar, a insuficiência ou estenose pulmonar residual
pode acarretar falência cardíaca direita com deterioração
clínica. Essas crianças necessitam de múltiplas intervenções
ao longo de suas vidas, que impõem uma elevada taxa de
morbidade e mortalidade.
Objetivo: Desenvolvimento de uma técnica menos
invasiva para implante de uma prótese valvada através do
ventrículo direito.
Métodos: A prótese valvada consiste em um anel metálico
construído com nitinol autoexpansível, revestida de
poliéster, onde três cúspides de pericárdio bovino foram
montadas. Doze porcos foram utilizados para a realização
dos implantes. Foi realizado controle ecocardiográfico
imediatamente após o implante e com uma, quatro, oito e
12 semanas.
Resultados: Um animal apresentou refluxo de grau
moderado a importante e outros três refluxo de grau leve.
Os gradientes transvalvares medidos antes do implante
variavam entre 3 a 6 mmHg, sendo que, logo após o implante,
houve aumento dos gradientes que variaram de 7 a 45 mmHg.
Houve queda desses gradientes, sendo que em apenas quatro
dos 12 animais os gradientes estavam acima de 20 mmHg.
Em seis animais, ocorreu a formação de trombo na prótese,
sendo esta a complicação mais frequente.
Conclusão: Esses achados evidenciam a necessidade da
realização de estudos com a utilização de anticoagulantes e
ou antiagregantes plaquetários na tentativa de diminuir esse
evento. O estudo pretende apresentar subsídios para o início
do emprego de próteses valvares que poderiam ser
implantadas através de técnicas menos invasivas.
Descritores: Valva Pulmonar. Insuficiência da Valva
Pulmonar. Estenose da Valva Pulmonar. Anormalidades
Congênitas. Cardiopatia congênita.
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This study aims to develop a less invasive technique
for implantation of a prosthetic valve in the RVOT without
use of cardiopulmonary bypass, by transcatheter via
through the right ventricle.
The experimental protocol was performed at the Center
for Research and Training in Surgery (CETEC), Hospital
Israelita Albert Einstein (Figure 1). This research center in
experimental surgery has all the resources necessary to
perform the project as a team of anesthesiologists,
anesthesia machines, echocardiography and fluoroscopy
(arch in “C”), plus all the infrastructure to accommodate
and follow the animals after implant.
The models of stent valves are produced in partnership
with the private sector and Braile Biomédica, a Brazilian
company with extensive experience in commercial
bioprostheses and stents.
To perform the echocardiographic and hemodynamic
measures an echocardiography device - Envisor C Philips
Medical Systems (Eindhoven, the Netherlands) was used.
Measurements of the diameter of the RVOT, just below
the pulmonary valve ring, a cut in short axis of the pulmonary
artery to the level of the aortic valve were performed.
Assessments of hemodynamic and echocardiographic
measurements were performed before and immediately after
implantation. The measurements were repeated with one,
four, eight and twelve weeks of follow-up.
Histological evaluation was performed after removal of
the prosthesis.
Preparation of animals
All animals were treated according to international
ethical principles and those prepared by the Brazilian College
Fig. 1. Bovine pericardial valve prosthesis coated with polyester
The valve prosthesis consists of a metal ring, in
conformation with “Z”, built with nitinol (alloy of nickel
and titanium) selfexpandable, coated with polyester, where
three bovine pericardial leaflets were mounted to form a
valve. The prostheses were made with bovine pericardium,
and fixed in glutaraldehyde (Figure 1). The prostheses were
produced in four sizes with 20, 22, 24 and 26 millimeters
(mm) in diameter. The devices were tested in flow replicates,
with hemodynamic performance and durability comparable
to commercially available bioprostheses and released for
human use.
The device was implanted through the right ventricle of
the animal, according to the technique described below.
of Animal Experimentation (COBEA), by the Ethics
Committee on Animal Use (CEUA/Einstein).
Twelve Large White pigs, all castrated males, three months
old and weighing 25-32 kg were used to perform the implants.
All animals were fasted for 12 hours - solid and water -
for 6 hours prior to the procedure.
The choice of prosthesis size was based on the diameter
of the pulmonary valve annulus, which was measured, using
transthoracic echocardiography immediately after general
anesthesia of the animal. The diameter of the pulmonary
ring was added 20% to ensure a good coupling of the
prosthesis to the walls of the pulmonary artery. Thus, in 11
of 12 animals, the measurements were almost 20 mm, and a
24mm prosthesis was used. In an animal with an annulus
diameter of 17 mm, we chose to use a prosthesis size 22 (22
mm diameter).
After general anesthesia and tracheal intubation,
median sternotomy was performed, followed by
pericardiotomy and confection of purse-string suture with
5-0 green polyester yarn in the anterior right ventricle
(near the RVOT) for insertion of the prosthesis (Figure 2).
Puncture of the right ventricle with large-bore needle and
passage of guidewire into the distal pulmonary artery were
performed, followed by insertion of a pig-tail catheter.
Pulmonary arteriography was performed for localization
of the pulmonary valve. Pig-tail-type catheter was then
replaced by rigid guide wire on which the release device
of the prosthesis was placed (Figure 3). Releasing of the
prosthesis was performed in the position of the pulmonary
valve with the aid of fluoroscopy and echocardiography
(Figure 4).
After implantation, we performed measurements of
pressures in the right chamber, followed by arteriography
to confirm the absence of pulmonary valve regurgitation.
Postoperative follow-up was performed with
echocardiographic measurements of transvalvular gradients
with one, four, eight and 12 weeks.
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After removal of the prosthesis, all were washed with
saline solution (NaCl) 0.9% and fixed in formalin, and then
subjected to macroscopic and histopathological analysis.
RESULTS
All prostheses were implanted with the intention of
the native pulmonary valve was pressed against the walls
of the pulmonary artery. However, accidentally, in three
animals the prosthesis was implanted in the pulmonary
artery trunk.
Eleven of the 12 implanted prostheses proved to be
competent to angiography after implantation. Only in one
animal perivalvar leak was present shortly after implantation,
this being quantified as moderate to severe, or three crosses
on a scale of one to four (where one means minimal
regurgitation, and four major reflux).
Periprosthetic reflux was observed in five of the
following twelve animals, and there was only a moderate to
severe reflux, this soon after the implant, as mentioned
above. The other four animals showed only a mild (+/4 +),
which was diagnosed in the first week in three animals, and
in the fourth week in one of them. In one of the animals
showed reflux in the first week, there was regression of
reflux in the fourth week of follow-up. In one animal, the
reflux was detected after migration of the prosthesis from
its initial position to the pulmonary artery, in other animals,
reflux was not preceded or accompanied by other changes.
The presence of reflux did not affect the evolution of these
animals.
Migration of the prosthesis was diagnosed in two
animals, both in the first week of follow-up, leading to the
appearance of mild reflux (+/4+) in one of the animals, as
previously reported.
The echocardiographic evaluation showed thrombus
formation on the prosthesis in six of 12 animals. Of these, in
one animal, the thrombus was diagnosed in the first week
of follow-up, and in five other animals, the diagnosis was
confirmed in the fourth week of follow-up. In three animals,
the presence of thrombus resonated with increased gradient
of 15 to 42 mmHg, from 17 to 24 mmHg and from 8 to 45
mmHg, respectively.
Two animals were found dead in the stalls, one with
31 days and another with 85 days of follow-up. In none
of these animals there was thrombus formation in the
prosthesis on autopsy. In one of these animals occurred
minimal regurgitation (+4/+), which was diagnosed the
day before the finding of death. Two other animals have
evolved presenting surgical wound infection, both
sacrif iced at  11 and 17 days postoperat ively,
respectively. Also, in these animals there was no
thrombus on the prosthesis or evidence of dysfunction
at autopsy.Fig. 4. Radioscopic image of the valve placed after the implant
Fig. 3. Device (introducer) prepared containing the prosthesis to
the implant
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Fig. 2. Right ventricle anterior side.
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There was considerable increase in the gradients
between the right ventricle and pulmonary artery,
immediately after implantation of the prosthesis. The values
†of the gradients pre-implantation ranged from 3 to 6 mmHg
(mean 4.1 mmHg), which have risen from 7 to 45 mmHg
(mean 18.6 mmHg) after implantation. The
echocardiographic measurements during follow-up showed
a gradual decrease in the values  of pulmonary gradients,
and in only four of 12 animals, the gradients remained above
20 mmHg (23, 24, 42 and 59) (Figure 5).
Macroscopic analysis performed showed good fixation
of the prosthesis to the wall of the pulmonary artery.
Presence of macroscopic thrombus was observed in six of
12 animals at autopsy, as diagnosed by echocardiography,
and it has been described previously. M i c r o s c o p y
showed a satisfactory outcome, with little inflammatory
infiltrate in the valve leaflets.
DISCUSSION
RVOT dysfunction represents a major problem in
patients undergoing surgery for congenital heart diseases,
especially where there is need for reconstruction of the
RVOT. This regurgitation can lead to severe right ventricular
dysfunction [17]. Sometimes, the right ventricular
dysfunction can be reversed when the valve replacement
is performed. However, if the replacement is performed later,
these changes can be permanent [18].
The pulmonary valve replacement is recommended in
patients with deterioration of clinical or objective signs of
right ventricular dysfunction. The surgical procedure, with
the pulmonary valve replacement (or RVOT), is the strategy
used that is able to improve clinical status and patient
survival. However, the cardiopulmonary bypass used for
valve replacement may worsen right ventricular
dysfunction, and the risks inherent in a reoperation,
reducing the clinical benefit of valve replacement [19].
For pulmonary valve replacement, various materials can
be used, the most frequent are the homografts, porcine
pulmonary valves and prostheses made from bovine
pericardium. Another material widely used in recent years
is from the bovine jugular vein, which has shown good
results [20-22].
More recently, the percutaneous treatment of pulmonary
insufficiency has shown a promising field, with the
possibility of correction of pulmonary insufficiency without
the adverse effects and risks associated with the
conventional CPB [12].
Together with the private sector, we developed a
prosthetic valve consisted of a nitinol stent covered with
polyester, in which a bovine pericardial valve was mounted.
Percutaneous treatment of valvular dysfunction and aortic
stenosis has been performed widely throughout the world,
including our institution [23-25].
In our study, nine of 12 animals underwent implantation
of heart valve prosthesis successfully. In three animals,
the prosthesis was introduced accidentally in the
pulmonary artery trunk. However, none of these had reflux
immediately after the implant, or graft dysfunction during
the follow-up. Different from the reported by Bonhoeffer et
al. [12] in their experimental study in sheep, in which the
animals who received stents out of the preconized location,
covering the pulmonary valve, and presenting dysfunction
of the prosthesis.
Five of 12 animals showed perivalvar reflux after
implantation, and in one the reflux was graded as moderate
to severe just after implantation, although the prosthesis
has been released in the correct position (pulmonary
valve). One explanation for the development of reflux may
be inadequate estimation of the size of the pulmonary
annulus. This animal received a 24mm prosthesis (20%
above the pulmonary annulus diameter), a size considered
by us to provide adequate radial force sufficient to
maintain the prosthesis coapted to the pulmonary artery
wall. In the other four animals, reflux grade was estimated
as minimal (+/4+), causing no clinical consequences to
animals, these results comparable to those presented by
other authors [12].
Migration of the prosthesis to the pulmonary artery
occurred in two animals, both in the first week, and in one
patient presented minimal regurgitation (+/4+), also
without effect. One hypothesis for the migration of the
device would once again be an underestimation of the
diameter of the pulmonary annulus, which would result in
a choice of prosthesis with insufficient size, thus providing
lower radial force to the prosthesis, which would facilitate
its migration. The diameter of the prostheses used were
both 24 mm diameter retaining 20%  †above the pulmonary
annulus measured prior to implantation (20 mm in two
animals).
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Fig. 5. Evolution of the gradient (in mmHg) through the prosthesis
during the follow-up
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The formation of thrombus on the prosthesis was the
most frequent complication, affecting six of the twelve
animals. In one animal, the thrombus was evidenced in the
first week, in the other five the diagnosis was performed in
the fourth week of follow-up. Of the six animals with
thrombus, in three there was a higher gradient in the lung
to more than 20 mmHg (24, 42 and 45). The high rate of
thrombosis found can be explained by factors such as the
tendency to hypercoagulability found in pigs, the presence
of low flow in the right heart chambers and the possible
presence of bacterial endocarditis by contamination at the
time of implantation, as reported by others [12]. These
findings highlight the need for studies with the use of
anticoagulants or antiplatelet agents in an attempt to reduce
this event and an special care in aseptic handling during
implantation.
Despite the high rate of thrombosis found in our
study, the possibility of treatment via transcatheter
pulmonary valve dysfunction without the need for
extracorporeal circulation, with less invasive technique
may benefit a large proportion of pediatric and adult
patients in the coming years. The prostheses presented
in this study are available in a variety of sizes, which
allows the treatment of patients with different degrees
of dilation of the RVOT, an advantage over the prosthesis
on the market today [26].
The study aims to provide subsidies to the beginning
of the use of prosthetic heart valves that could be implanted
through less invasive techniques for the treatment of RVOT
dysfunction, commonly seen in postoperative pediatric
cardiac surgery.
We believe that the development of such devices with
national technology could benefit a large number of children
and young adults suffering from dysfunction of the RVOT
and require frequent surgical interventions.
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